Financial Performance - For Q1 2024, the company's operating revenue was RMB 221,850,180.79, representing a decrease of 9.95% compared to the same period last year[5]. - The net profit attributable to shareholders was RMB 55,199,616.28, reflecting a decline of 1.18% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was RMB 48,882,462.10, down by 1.46% compared to the previous year[6]. - Basic and diluted earnings per share were both RMB 0.14, a decrease of 6.67% year-on-year[6]. - Operating profit for Q1 2024 was $59.33 million, a decrease of 3.25% from $62.34 million in Q1 2023[19]. - Total profit for Q1 2024 was $60.16 million, down from $62.23 million in the same period last year, representing a decline of 3.41%[19]. - Net profit attributable to shareholders for Q1 2024 was $55.20 million, compared to $55.86 million in Q1 2023, reflecting a decrease of 1.18%[19]. Cash Flow - The net cash flow from operating activities was negative at RMB -129,613,339.07, indicating a significant cash outflow[6]. - Cash inflow from operating activities for Q1 2024 was $217.43 million, slightly up from $212.80 million in Q1 2023, an increase of 2.54%[20]. - Cash outflow from operating activities totaled $347.04 million in Q1 2024, compared to $333.00 million in Q1 2023, an increase of 4.22%[20]. - Net cash flow from operating activities was -$129.61 million in Q1 2024, worsening from -$120.20 million in Q1 2023[20]. - Cash inflow from investment activities was $837.23 million in Q1 2024, up from $771.18 million in Q1 2023, an increase of 8.56%[21]. - Cash outflow from investment activities was $753.50 million in Q1 2024, slightly down from $769.63 million in Q1 2023, a decrease of 2.09%[21]. - Net cash flow from investment activities was $83.73 million in Q1 2024, significantly up from $1.55 million in Q1 2023[21]. - Cash and cash equivalents at the end of Q1 2024 were $1.22 billion, compared to $838.34 million at the end of Q1 2023, an increase of 45.66%[22]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 3,542,662,190.69, down 2.93% from the end of the previous year[6]. - Total liabilities decreased to CNY 608,374,106.90 from CNY 770,325,491.93, a reduction of 21.03%[16]. - Current liabilities totaled CNY 514,691,217.05, down 23.99% from CNY 676,672,835.51 in the previous year[16]. - The company's cash and cash equivalents as of March 31, 2024, amount to ¥1,220,478,879.78, a decrease from ¥1,266,367,522.67 at the end of 2023[14]. - The company's inventory as of March 31, 2024, is ¥476,158,025.23, an increase from ¥434,485,725.70 at the end of 2023[14]. - The company's accounts receivable increased to ¥418,285,561.50 from ¥405,895,527.39 at the end of 2023[14]. - The total trading financial assets decreased to ¥741,195,087.52 from ¥832,019,095.90 at the end of 2023[14]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,133, with 6,116 A-share holders and 17 H-share holders[11]. - The largest shareholder, Shi Chunbao, holds 114,840,685 shares, representing 29.94% of the total shares[10]. - The second-largest shareholder, Yue Shujun, holds 95,447,900 shares, accounting for 24.88% of the total shares[10]. - The company has not reported any changes in the top 10 shareholders due to securities lending activities[12]. - The company has not disclosed any related party relationships among the top 10 shareholders[11]. Research and Development - Research and development expenses totaled RMB 34,991,868.71, accounting for 15.77% of operating revenue, an increase of 2.26 percentage points year-on-year[6]. - Research and development expenses increased to CNY 34,991,868.71, up 5.18% from CNY 33,270,315.66 in Q1 2023[18]. Government Subsidies - The company recognized government subsidies amounting to RMB 2,607,636.22 as part of non-recurring gains[7]. - The company reported a total of RMB 6,317,154.18 in non-recurring gains after tax, indicating ongoing financial impacts from certain government policies[8]. Operational Situation - There are no significant reminders regarding the company's operational situation during the reporting period[13].
春立医疗(01858) - 2024 Q1 - 季度业绩